Temporal Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients between 2004 and 2019

被引:1
|
作者
Gorczyca-Glowacka, Iwona [1 ,2 ]
Bielecka, Bernadetta [2 ]
Walek, Pawel [1 ,2 ]
Chrapek, Magdalena [3 ]
Ciba-Stemplewska, Agnieszka [4 ]
Jelonek, Olga [1 ,2 ]
Kot, Anna [2 ]
Czyzyk, Anna [1 ]
Pioro, Maciej [1 ]
Major, Agnieszka [1 ,2 ]
Wozakowska-Kaplon, Beata [1 ,2 ]
机构
[1] Jan Kochanowski Univ, Coll Med, PL-25369 Kielce, Poland
[2] Swietokrzyskie Cardiol Ctr, Clin Cardiol & Electrotherapy 1, PL-25736 Kielce, Poland
[3] Jan Kochanowski Univ, Fac Nat Sci, PL-25369 Kielce, Poland
[4] Integrated Prov Hosp, Dept Internal Med, PL-25736 Kielce, Poland
关键词
atrial fibrillation; non-vitamin K antagonist oral anticoagulants; oral anticoagulants; vitamin K antagonists; STROKE PREVENTION; WARFARIN; THROMBOEMBOLISM; IMPACT; RISK;
D O I
10.3390/ijerph19095584
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Background: In the recent years, antithrombotic prophylaxis in patients with atrial fibrillation (AF) has changed significantly. The main aim of this study is to assess the temporal trends of antithrombotic therapy and identify factors predisposing oral anticoagulant (OAC) use in stroke prevention in AF patients. Methods: The present study is a retrospective, observational, single-center study, which includes consecutively hospitalized patients in the reference cardiology center from January 2004 to December 2019. Results: A total of 9656 patients (43.7% female, mean age 71.2 years) with AF between 2004-2019 are included. Among the total study population, in most of the patients (81.1%), OAC therapy was used, antiplatelet (APT) therapy was prescribed for 13.5% patients, heparins for 2.1% patients and 3.3% of patients did not receive any stroke prevention. OAC prescription significantly increased from 61.6% in 2004 to 97.4% in 2019. The independent predictors of OAC prescription were: the period of hospitalization, non-paroxysmal AF, age, hypertension, diabetes mellitus, previous thromboembolism, hospitalization due to electrical cardioversion, ablation or AF without any procedures. Conclusions: In hospitalized patients with AF, during sixteen years of the study period, a significant increase in OAC use and a decrease in APT use were noted. Factors other than these included in the CHA(2)DS(2)-VASc score were independent predictors of OAC use.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Prescription of oral anticoagulation in geriatric patients with atrial fibrillation
    Ramirez-Prieto, Genesis
    Pombo-Bartelt, Jose E.
    Rojas-Calderon, Guadalupe
    Garcia-Gonzalez, Jose J.
    [J]. ARCHIVOS DE CARDIOLOGIA DE MEXICO, 2022, 92 (01): : 42 - 52
  • [32] Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant
    Hale, Zachary D.
    Kong, Xiowen
    Haymart, Brian
    Gu, Xiaokui
    Kline-Rogers, Eva
    Almany, Steve
    Kozlowski, Jay
    Krol, Gregory D.
    Kaatz, Scott
    Froehlich, James B.
    Barnes, Geoffrey D.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2017, 43 (02) : 283 - 288
  • [33] Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant
    Zachary D. Hale
    Xiowen Kong
    Brian Haymart
    Xiaokui Gu
    Eva Kline-Rogers
    Steve Almany
    Jay Kozlowski
    Gregory D. Krol
    Scott Kaatz
    James B. Froehlich
    Geoffrey D. Barnes
    [J]. Journal of Thrombosis and Thrombolysis, 2017, 43 : 283 - 288
  • [34] Trends in Atrial Fibrillation and Prescription of Oral Anticoagulants and Embolic Strokes in Germany
    Guelker, Jan-Erik
    Bufe, Alexander
    Klues, Heinrich
    Shin, Dong-In
    Blockhaus, Christian
    Gabriel, Nils-Holger
    Haverkamp, Wilhelm
    Kroeger, Knut
    [J]. CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2019, 20 (05) : 399 - 402
  • [35] Anticoagulant Utilization and Direct Oral Anticoagulant Prescribing in Patients with Nonvalvular Atrial Fibrillation
    Shum, Priscilla
    Klammer, Gordon
    Toews, Dale
    Barry, Arden
    [J]. CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2019, 72 (06): : 428 - 434
  • [36] Which Oral Anticoagulant for Atrial Fibrillation?
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1492): : 45 - 46
  • [37] Choice of an Oral Anticoagulant in Atrial Fibrillation
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2012, 54 (1400): : 79 - 80
  • [38] WORLDWIDE ORAL ANTICOAGULANT PRESCRIPTION PREVALENCE AND TRENDS IN PATIENTS WITH ATRIAL FIBRILLATION FROM A MULTI-NATIONAL COHORT: INSIGHTS FROM THE INTERNATIONAL COLLABORATIVE PARTNERSHIP FOR THE STUDY OF ATRIAL FIBRILLATION (INTERAF) COLLABORATIVE
    Hsu, Jonathan Chong
    Akao, Masaharu
    Avezum Junior, Alvaro
    Bloomfield, Gerald
    Kohsaka, Shun
    Lane, Deirdre
    Lip, Gregory
    Ma, Chang-Sheng
    Ogawa, Hisashi
    Ponirakis, Angelo
    Potpara, Tatjana
    Refaat, Marwan
    Temu, Tecla
    Teo, Wee Siong
    Tse, Hung-Fat
    Maddox, Thomas
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 376 - 376
  • [39] Longitudinal Oral Anticoagulant Adherence Trajectories in Patients With Atrial Fibrillation
    Salmasi, Shahrzad
    De Vera, Mary A.
    Safari, Abdollah
    Lynd, Larry D.
    Koehoorn, Mieke
    Barry, Arden R.
    Andrade, Jason G.
    Deyell, Marc W.
    Rush, Kathy
    Zhao, Yinshan
    Loewen, Peter
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (24) : 2395 - 2404
  • [40] Oral Anticoagulant Discontinuation and Its Predictors in Patients with Atrial Fibrillation
    Kefale, Adane Teshome
    Bezabhe, Woldesellassie M.
    Peterson, Gregory M.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)